- Home
- HBCP vs ALT Comparison
HBCP vs ALT Comparison
Compare HBCP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBCP | ALT |
|---|---|---|
| Founded | 1908 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 421.5M |
| IPO Year | 2008 | 2005 |
Fundamental Metrics
Financial Performance| Metric | HBCP | ALT |
|---|---|---|
| Price | $63.50 | $3.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $65.50 | $17.67 |
| AVG Volume (30 Days) | 110.4K | ★ 4.5M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 29.01 | 25.37 |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.97 | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $47.96 | $2.56 |
| 52 Week High | $65.95 | $7.73 |
Technical Indicators
Market Signals| Indicator | HBCP | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 44.20 |
| Support Level | $56.72 | $2.87 |
| Resistance Level | $65.00 | $4.25 |
| Average True Range (ATR) | 1.67 | 0.18 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 44.03 | 40.28 |
Price Performance
Historical ComparisonAbout HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.